A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
The purpose of this study was to evaluate the efficacy and safety of tislelizumab as second line treatment in participants with advanced unresectable/metastatic ESCC that had progressed during or after first line therapy.
Epistemonikos ID: e32e60c8e48858c5c6e5ffbc34a006e8f7925948
First added on: May 21, 2024